[Hemolytic-uremic syndrome caused by mitomycin c: long-term management].
We describe the case of a 51-year-old woman who developed a hemolytic uremic syndrome nine weeks after the end of chemotherapy with mitomycin C for cancer of the anus. Episodes of hemolytic uremic syndrome recurred within a period of up to six months. They were treated with plasma infusion and exchange, antiplatelet agents and rigorous control of blood pressure. The patient was followed for eight years. Her blood pressure has been normal without the use of antihypertensive agents and the renal function has remained stable with serum creatinine at 110 mumol/1. The tumor has remained in remission. This case suggests that recovery from the acute phase of hemolytic uremic syndrome leads to good long-term prognosis.
Duvic
C
C
Clinique de Néphrologie, Hôpital d'Instruction des Armées du Val-de-Grâce, Paris.
Sarret
D
D
Coutant
G
G
Herody
M
M
Didelot
F
F
Nedelec
G
G
D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D001005:Anus Neoplasms / Q000188:drug therapy; D001794:Blood Pressure; D003404:Creatinine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced* / Q000628:therapy; D006801:Humans; D007668:Kidney / Q000502:physiology; D008137:Longitudinal Studies; D008875:Middle Aged; D016685:Mitomycin / Q000009:adverse effects*; D010951:Plasma Exchange; D010952:Plasma Substitutes / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011379:Prognosis; D012008:Recurrence
D000903:Antibiotics, Antineoplastic; D010952:Plasma Substitutes; D010975:Platelet Aggregation Inhibitors; D016685:Mitomycin; D003404:Creatinine